Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Biosciences, a provider of nanoproteomic analysis systems, has closed a $10 million series C financing led by its largest shareholder, the Wellcome Trust.
Subscribe to our email newsletter
Existing investors Domain Associates, Latterell Venture Partners, Novo, Mitsui Ventures, Royal Bank of Canada and The Vertical Group also participated in the financing.
Tim Harkness, president and CEO of Cell Biosciences, said: “We are very happy to announce this financing in the current economic environment and we believe it represents a strong vote of confidence by our investors in the potential of the technology and team at Cell Biosciences.
“This investment should allow us to fully execute our plan to bring this revolutionary proteomics technology to the broad life sciences market.”